Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 01:16am CEST

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; [email protected]

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA PLC
07:19p ASTRAZENECA : trial indicates diabetes drug had no big cardiac side-effects
01:06p ASTRAZENECA : BYDUREON EXSCEL Trial Meets Primary Safety Objective in Type-2 Dia..
08:35aDJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
08:01a ASTRAZENECA : Bydureon EXSCEL trial meets T2D safety objective
07:11a ASTRAZENECA : in $300m deal for heart medicine
05/22 ASTRAZENECA : Phase III ZONDA Trial for benralizumab Shows Ability to Reduce Ora..
05/22 ASTRAZENECA : enters agreement with Recordati for Seloken in Europe
05/22DJASTRAZENECA : in Pact with Recordati for Heart-Drug Seloken in Europe
05/19 ASTRAZENECA : Brodalumab receives positive CHMP opinion for the treatment of adu..
05/19 ASTRAZENECA : China Medical City builds on AstraZenica success with new UK incub..
More news
Sector news : Pharmaceuticals - NEC
10:05pDJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
07:16pDJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
07:10pDJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- Update
03:53pDJALEXION PHARMACEUTICALS : Management Shakeup Continues as Four More Executives E..
02:15p UK competition watchdog accuses Merck of obstructing biosimilars
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07:44a Study shows AstraZeneca's T2D med Bydureon does not increase CV risk
06:07a Don't Give Up On Splunk - Cramer's Lightning Round (5/22/17)
05:28a Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2017 Update
05/22 AstraZeneca's benralizumab shows significant treatment effect in severe asthm..
05/22 Astrazeneca's Dealing Cannot Mask Its Problems
Advertisement
Financials ($)
Sales 2017 21 490 M
EBIT 2017 5 797 M
Net income 2017 2 671 M
Debt 2017 12 526 M
Yield 2017 4,09%
P/E ratio 2017 30,59
P/E ratio 2018 24,42
EV / Sales 2017 4,52x
EV / Sales 2018 4,41x
Capitalization 84 627 M
More Financials
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 65,9 $
Spread / Average Target -1,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC15.61%84 627
JOHNSON & JOHNSON10.23%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.11%191 279
MERCK & CO., INC.8.78%175 160
More Results